While the rapid growth of the GLP-1 and obesity market presents enormous financial opportunities for life sciences companies, it also carries legal, regulatory, and reimbursement risks
In recent years, the landscape of weight-loss injections has shifted dramatically: from older GLP-1 medications to dual-agonists such as Mounjaro , and now to even more ambitious agents such as Retatrutide
This is critical in reducing the risk of obesity-related conditions, such as heart disease, stroke, and type 2 diabetes
Importantly, a substantial number of patients had multiple reasons noted for stopping (21%), underscoring the complexity of real-world medication use and the challenges patients face when using these therapies
On average, GLP-1s can lead to 15% or more body weight reduction, and for those who have lived with obesity for years, their lives will change dramatically. Tran says using GLP-1s can lead to less spending on food, with users eating smaller portions, cutting unnecessary snacking, finding fast food less appealing, and experiencing reduced cravings for high-sugar foods
The Modern Peptides team can help with product documentation, secure checkout, order status, tracking, and account questions through live chat, email, or phone